Biotechnology Partnership Seeks to Expand Rett Syndrome Drug into European Market

3 min read | January 15, 2025 11:00 AM AEDT | By Team Kalkine Media

Biotechnology Partnership Seeks to Expand Rett Syndrome Drug into European Market — Image source: Shutterstock

Neuren Pharmaceuticals and Trofinetide's European Debut

Neuren Pharmaceuticals (ASX:NEU) has made significant strides as its partner, Acadia Pharmaceuticals, has officially submitted a marketing authorisation application to the European Medicines Agency for trofinetide. This application seeks approval for the treatment of Rett syndrome in both adults and children aged two and above. If approved, trofinetide would emerge as the first and only authorised therapy for Rett syndrome within the European Union. Acadia anticipates potential approval by Q1 of CY26 and plans to initiate managed access programs in Europe by Q2 2025. The treatment, under the name Daybue, has already gained approval in the US and Canada. This advancement marks a pivotal achievement in providing therapeutic relief to the Rett community across Europe.

Compumedics' Remarkable Growth Trajectory

Compumedics (ASX:CMP), revered for its diagnostic technologies, has experienced an unprecedented surge in sales orders, amounting to $32.8 million in H1 FY25. The key driver of this growth is the escalating demand in the US market, where sales orders soared 208% compared to the previous year. Notably, the company's sleep and Neuroscan brain analysis sectors are at the forefront of this advancement. Compumedics launched its Somfit device in the US, achieving initial sales of $700k within merely six months. The company forecasts accelerated growth in H2 FY25 as it enhances its sales resources and expands its business with independent diagnostic testing facilities. Global collaborations, including an initial order from a CPAP entity, further bolster Compumedics' global presence.

Tryptamine Therapeutics in the Spotlight

Tryptamine Therapeutics (ASX:TYP) is set to present its pioneering biotech solutions at the Biotech Showcase 2025 in San Francisco. Renowned for its development of IV-infused psilocin solutions, Tryptamine is addressing critical unmet medical needs. Their lead asset, TRP-8803, offers revolutionary improvements in treatment, including quicker administration times and the flexibility to reverse treatment when needed. After successful phase II trials for binge eating disorder and fibromyalgia, along with phase I studies to optimize infusion rates, the company is advancing to clinical studies in Australia. As one of 400 global companies participating in the showcase, Tryptamine finds itself at the forefront of significant investor interest, engaging with investor groups managing over $400 billion in capital.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.